{
    "id": "dbpedia_6046_3",
    "rank": 95,
    "data": {
        "url": "https://www.slideshare.net/slideshow/sinopharm-guide-covid19-vaccine/250907005",
        "read_more_link": "",
        "language": "en",
        "title": "Sinopharm guide Covid-19 vaccine",
        "top_image": "https://cdn.slidesharecdn.com/ss_thumbnails/sinopharmtrainingguide-2912021-211227203913-thumbnail.jpg?width=640&height=640&fit=bounds",
        "meta_img": "https://cdn.slidesharecdn.com/ss_thumbnails/sinopharmtrainingguide-2912021-211227203913-thumbnail.jpg?width=640&height=640&fit=bounds",
        "images": [
            "https://public.slidesharecdn.com/images/next/svg/logo/slideshare-scribd-company.svg?w=128&q=75 1x, https://public.slidesharecdn.com/images/next/svg/logo/slideshare-scribd-company.svg?w=256&q=75 2x",
            "https://image.slidesharecdn.com/sinopharmtrainingguide-2912021-211227203913/85/Sinopharm-guide-Covid-19-vaccine-1-320.jpg 320w, https://image.slidesharecdn.com/sinopharmtrainingguide-2912021-211227203913/85/Sinopharm-guide-Covid-19-vaccine-1-638.jpg 638w, https://image.slidesharecdn.com/sinopharmtrainingguide-2912021-211227203913/75/Sinopharm-guide-Covid-19-vaccine-1-2048.jpg 2048w",
            "https://image.slidesharecdn.com/sinopharmtrainingguide-2912021-211227203913/85/Sinopharm-guide-Covid-19-vaccine-2-320.jpg 320w, https://image.slidesharecdn.com/sinopharmtrainingguide-2912021-211227203913/85/Sinopharm-guide-Covid-19-vaccine-2-638.jpg 638w, https://image.slidesharecdn.com/sinopharmtrainingguide-2912021-211227203913/75/Sinopharm-guide-Covid-19-vaccine-2-2048.jpg 2048w",
            "https://image.slidesharecdn.com/sinopharmtrainingguide-2912021-211227203913/85/Sinopharm-guide-Covid-19-vaccine-3-320.jpg 320w, https://image.slidesharecdn.com/sinopharmtrainingguide-2912021-211227203913/85/Sinopharm-guide-Covid-19-vaccine-3-638.jpg 638w, https://image.slidesharecdn.com/sinopharmtrainingguide-2912021-211227203913/75/Sinopharm-guide-Covid-19-vaccine-3-2048.jpg 2048w",
            "https://image.slidesharecdn.com/sinopharmtrainingguide-2912021-211227203913/85/Sinopharm-guide-Covid-19-vaccine-4-320.jpg 320w, https://image.slidesharecdn.com/sinopharmtrainingguide-2912021-211227203913/85/Sinopharm-guide-Covid-19-vaccine-4-638.jpg 638w, https://image.slidesharecdn.com/sinopharmtrainingguide-2912021-211227203913/75/Sinopharm-guide-Covid-19-vaccine-4-2048.jpg 2048w",
            "https://image.slidesharecdn.com/sinopharmtrainingguide-2912021-211227203913/85/Sinopharm-guide-Covid-19-vaccine-5-320.jpg 320w, https://image.slidesharecdn.com/sinopharmtrainingguide-2912021-211227203913/85/Sinopharm-guide-Covid-19-vaccine-5-638.jpg 638w, https://image.slidesharecdn.com/sinopharmtrainingguide-2912021-211227203913/75/Sinopharm-guide-Covid-19-vaccine-5-2048.jpg 2048w",
            "https://image.slidesharecdn.com/sinopharmtrainingguide-2912021-211227203913/85/Sinopharm-guide-Covid-19-vaccine-6-320.jpg 320w, https://image.slidesharecdn.com/sinopharmtrainingguide-2912021-211227203913/85/Sinopharm-guide-Covid-19-vaccine-6-638.jpg 638w, https://image.slidesharecdn.com/sinopharmtrainingguide-2912021-211227203913/75/Sinopharm-guide-Covid-19-vaccine-6-2048.jpg 2048w",
            "https://image.slidesharecdn.com/sinopharmtrainingguide-2912021-211227203913/85/Sinopharm-guide-Covid-19-vaccine-7-320.jpg 320w, https://image.slidesharecdn.com/sinopharmtrainingguide-2912021-211227203913/85/Sinopharm-guide-Covid-19-vaccine-7-638.jpg 638w, https://image.slidesharecdn.com/sinopharmtrainingguide-2912021-211227203913/75/Sinopharm-guide-Covid-19-vaccine-7-2048.jpg 2048w",
            "https://image.slidesharecdn.com/sinopharmtrainingguide-2912021-211227203913/85/Sinopharm-guide-Covid-19-vaccine-8-320.jpg 320w, https://image.slidesharecdn.com/sinopharmtrainingguide-2912021-211227203913/85/Sinopharm-guide-Covid-19-vaccine-8-638.jpg 638w, https://image.slidesharecdn.com/sinopharmtrainingguide-2912021-211227203913/75/Sinopharm-guide-Covid-19-vaccine-8-2048.jpg 2048w",
            "https://image.slidesharecdn.com/sinopharmtrainingguide-2912021-211227203913/85/Sinopharm-guide-Covid-19-vaccine-9-320.jpg 320w, https://image.slidesharecdn.com/sinopharmtrainingguide-2912021-211227203913/85/Sinopharm-guide-Covid-19-vaccine-9-638.jpg 638w, https://image.slidesharecdn.com/sinopharmtrainingguide-2912021-211227203913/75/Sinopharm-guide-Covid-19-vaccine-9-2048.jpg 2048w",
            "https://image.slidesharecdn.com/sinopharmtrainingguide-2912021-211227203913/85/Sinopharm-guide-Covid-19-vaccine-10-320.jpg 320w, https://image.slidesharecdn.com/sinopharmtrainingguide-2912021-211227203913/85/Sinopharm-guide-Covid-19-vaccine-10-638.jpg 638w, https://image.slidesharecdn.com/sinopharmtrainingguide-2912021-211227203913/75/Sinopharm-guide-Covid-19-vaccine-10-2048.jpg 2048w",
            "https://image.slidesharecdn.com/sinopharmtrainingguide-2912021-211227203913/85/Sinopharm-guide-Covid-19-vaccine-11-320.jpg 320w, https://image.slidesharecdn.com/sinopharmtrainingguide-2912021-211227203913/85/Sinopharm-guide-Covid-19-vaccine-11-638.jpg 638w, https://image.slidesharecdn.com/sinopharmtrainingguide-2912021-211227203913/75/Sinopharm-guide-Covid-19-vaccine-11-2048.jpg 2048w",
            "https://image.slidesharecdn.com/sinopharmtrainingguide-2912021-211227203913/85/Sinopharm-guide-Covid-19-vaccine-12-320.jpg 320w, https://image.slidesharecdn.com/sinopharmtrainingguide-2912021-211227203913/85/Sinopharm-guide-Covid-19-vaccine-12-638.jpg 638w, https://image.slidesharecdn.com/sinopharmtrainingguide-2912021-211227203913/75/Sinopharm-guide-Covid-19-vaccine-12-2048.jpg 2048w",
            "https://image.slidesharecdn.com/sinopharmtrainingguide-2912021-211227203913/85/Sinopharm-guide-Covid-19-vaccine-13-320.jpg 320w, https://image.slidesharecdn.com/sinopharmtrainingguide-2912021-211227203913/85/Sinopharm-guide-Covid-19-vaccine-13-638.jpg 638w, https://image.slidesharecdn.com/sinopharmtrainingguide-2912021-211227203913/75/Sinopharm-guide-Covid-19-vaccine-13-2048.jpg 2048w",
            "https://image.slidesharecdn.com/sinopharmtrainingguide-2912021-211227203913/85/Sinopharm-guide-Covid-19-vaccine-14-320.jpg 320w, https://image.slidesharecdn.com/sinopharmtrainingguide-2912021-211227203913/85/Sinopharm-guide-Covid-19-vaccine-14-638.jpg 638w, https://image.slidesharecdn.com/sinopharmtrainingguide-2912021-211227203913/75/Sinopharm-guide-Covid-19-vaccine-14-2048.jpg 2048w",
            "https://image.slidesharecdn.com/sinopharmtrainingguide-2912021-211227203913/85/Sinopharm-guide-Covid-19-vaccine-15-320.jpg 320w, https://image.slidesharecdn.com/sinopharmtrainingguide-2912021-211227203913/85/Sinopharm-guide-Covid-19-vaccine-15-638.jpg 638w, https://image.slidesharecdn.com/sinopharmtrainingguide-2912021-211227203913/75/Sinopharm-guide-Covid-19-vaccine-15-2048.jpg 2048w",
            "https://image.slidesharecdn.com/sinopharmtrainingguide-2912021-211227203913/85/Sinopharm-guide-Covid-19-vaccine-16-320.jpg 320w, https://image.slidesharecdn.com/sinopharmtrainingguide-2912021-211227203913/85/Sinopharm-guide-Covid-19-vaccine-16-638.jpg 638w, https://image.slidesharecdn.com/sinopharmtrainingguide-2912021-211227203913/75/Sinopharm-guide-Covid-19-vaccine-16-2048.jpg 2048w",
            "https://image.slidesharecdn.com/sinopharmtrainingguide-2912021-211227203913/85/Sinopharm-guide-Covid-19-vaccine-17-320.jpg 320w, https://image.slidesharecdn.com/sinopharmtrainingguide-2912021-211227203913/85/Sinopharm-guide-Covid-19-vaccine-17-638.jpg 638w, https://image.slidesharecdn.com/sinopharmtrainingguide-2912021-211227203913/75/Sinopharm-guide-Covid-19-vaccine-17-2048.jpg 2048w",
            "https://image.slidesharecdn.com/sinopharmtrainingguide-2912021-211227203913/85/Sinopharm-guide-Covid-19-vaccine-18-320.jpg 320w, https://image.slidesharecdn.com/sinopharmtrainingguide-2912021-211227203913/85/Sinopharm-guide-Covid-19-vaccine-18-638.jpg 638w, https://image.slidesharecdn.com/sinopharmtrainingguide-2912021-211227203913/75/Sinopharm-guide-Covid-19-vaccine-18-2048.jpg 2048w",
            "https://image.slidesharecdn.com/sinopharmtrainingguide-2912021-211227203913/85/Sinopharm-guide-Covid-19-vaccine-19-320.jpg 320w, https://image.slidesharecdn.com/sinopharmtrainingguide-2912021-211227203913/85/Sinopharm-guide-Covid-19-vaccine-19-638.jpg 638w, https://image.slidesharecdn.com/sinopharmtrainingguide-2912021-211227203913/75/Sinopharm-guide-Covid-19-vaccine-19-2048.jpg 2048w",
            "https://image.slidesharecdn.com/sinopharmtrainingguide-2912021-211227203913/85/Sinopharm-guide-Covid-19-vaccine-20-320.jpg 320w, https://image.slidesharecdn.com/sinopharmtrainingguide-2912021-211227203913/85/Sinopharm-guide-Covid-19-vaccine-20-638.jpg 638w, https://image.slidesharecdn.com/sinopharmtrainingguide-2912021-211227203913/75/Sinopharm-guide-Covid-19-vaccine-20-2048.jpg 2048w",
            "https://image.slidesharecdn.com/sinopharmtrainingguide-2912021-211227203913/85/Sinopharm-guide-Covid-19-vaccine-21-320.jpg 320w, https://image.slidesharecdn.com/sinopharmtrainingguide-2912021-211227203913/85/Sinopharm-guide-Covid-19-vaccine-21-638.jpg 638w, https://image.slidesharecdn.com/sinopharmtrainingguide-2912021-211227203913/75/Sinopharm-guide-Covid-19-vaccine-21-2048.jpg 2048w",
            "https://image.slidesharecdn.com/sinopharmtrainingguide-2912021-211227203913/85/Sinopharm-guide-Covid-19-vaccine-22-320.jpg 320w, https://image.slidesharecdn.com/sinopharmtrainingguide-2912021-211227203913/85/Sinopharm-guide-Covid-19-vaccine-22-638.jpg 638w, https://image.slidesharecdn.com/sinopharmtrainingguide-2912021-211227203913/75/Sinopharm-guide-Covid-19-vaccine-22-2048.jpg 2048w",
            "https://image.slidesharecdn.com/sinopharmtrainingguide-2912021-211227203913/85/Sinopharm-guide-Covid-19-vaccine-23-320.jpg 320w, https://image.slidesharecdn.com/sinopharmtrainingguide-2912021-211227203913/85/Sinopharm-guide-Covid-19-vaccine-23-638.jpg 638w, https://image.slidesharecdn.com/sinopharmtrainingguide-2912021-211227203913/75/Sinopharm-guide-Covid-19-vaccine-23-2048.jpg 2048w",
            "https://image.slidesharecdn.com/sinopharmtrainingguide-2912021-211227203913/85/Sinopharm-guide-Covid-19-vaccine-24-320.jpg 320w, https://image.slidesharecdn.com/sinopharmtrainingguide-2912021-211227203913/85/Sinopharm-guide-Covid-19-vaccine-24-638.jpg 638w, https://image.slidesharecdn.com/sinopharmtrainingguide-2912021-211227203913/75/Sinopharm-guide-Covid-19-vaccine-24-2048.jpg 2048w"
        ],
        "movies": [],
        "keywords": [],
        "meta_keywords": [
            ""
        ],
        "tags": null,
        "authors": [],
        "publish_date": "2021-12-27T20:39:13+00:00",
        "summary": "",
        "meta_description": "Sinopharm guide Covid-19 vaccine  - Download as a PDF or view online for free",
        "meta_lang": "en",
        "meta_favicon": "https://public.slidesharecdn.com/_next/static/media/favicon.7bc3d920.ico",
        "meta_site_name": "SlideShare",
        "canonical_link": "https://www.slideshare.net/slideshow/sinopharm-guide-covid19-vaccine/250907005",
        "text": "1. By Federal EPI Vaccination Guidelines for Sinopharm Vaccine\n\n2. Basic information about Sinopharm Vaccine (Vero Cell) 2 Source: Vaccination Guide for Pakistan - Sinopharm Vaccine (Vero Cell) Developed by: Sinopharm and BBIPS Name: SARS-CoV-2 Vaccine (Vero Cell), inactivated Composition: The Vaccine (Vero Cell), inactivated, formulated with SARS-CoV-2 strain which is inoculated on the Vero cells for culturing, virus harvesting, 8- propiciactone-inactivation, concentration and purification, then adsorbed with aluminium adjuvant to form the liquid vaccine Appearance: Semi-transparent turbid suspended with slight white colour The vaccine is used for people aged 18 years old and above\n\n3. Agenda for training 3 Vaccine cold chain and storage Target Population and Vaccination Stages Administration of vaccine, injection safety and waste disposal COVID-19 vaccine safety, warnings and contraindications Potential AEFI management and reporting Post vaccination counselling, evaluation and handling of emergencies\n\n4. Stage 1a: - Frontline essential health care workers Stage 1b: - Remaining Health care workers - Population over 60 - 64yrs Stage 2: - A defined proportion of remainder population (18 and above) Target population and phases Note: As per the Cabinet’s decision\n\n5. Agenda for training 5 Vaccine cold chain and storage Vaccination strategy Administration of vaccine, injection safety and waste disposal COVID-19 vaccine safety, warnings and contraindications Potential AEFI management and reporting Post vaccination counselling, evaluation and handling of emergencies\n\n6. Vaccine storage 6 Source: Vaccination Guide for Pakistan - Sinopharm Vaccine (Vero Cell) 1 Storage and transportation in refrigerated (2-8 ͦ C) condition, protected from light 2 Do not freeze the vaccine in any circumstance 3 Protect the vaccine from sun-light 4 Expiry is approximately 2 years\n\n7. Agenda for training 7 Vaccine cold chain and storage Vaccination strategy Administration of vaccine, injection safety and waste disposal COVID-19 vaccine safety, warnings and contraindications Potential AEFI management and reporting Post vaccination counselling, evaluation and handling of emergencies\n\n8. Inter-personal Communication (Provider to recipient) 8 Consent You are receiving this vaccine as you agreed by registering in the system The procedure This will be an injection into the upper part of your arm and will cause the usual slight pain. Do let us know if you experience something unusual. SOP following the injection After the injection, you are requested to stay here for observation of any problems, for a period of 30 minutes Confirmation Do you have any question, or shall we go ahead with the injection? Retention This is your first dose. Please revisit AVC for your second dose after 3 weeks.\n\n9. Vaccine administration and needle selection 9 Source: Vaccination Guide for Pakistan - Sinopharm Vaccine (Vero Cell) Administration: The recommended administration is through intramuscular route. The deltoid muscle of the non-dominant side is the preferred site of injection. Needle selection: The injection is placed at an angle of 90 degree using a 25-gauge needle (22-25 may be used). The length of the needle is (5⁄8 – 1 1⁄2 inch).\n\n10. Vaccine dosage 10 Source: Vaccination Guide for Pakistan - Sinopharm Vaccine (Vero Cell) Dosage: A pre-filled syringe containing 0.5mL of product will be used for administration. Each dose contains 6.5U of inactivated SARS-CoV-2 antigen. Individuals should receive 2 doses (0.5 mL each), 21 days apart (2~4 weeks). 0.5ml 0.5ml Day 0: Day 21: 1st dose 2nd dose\n\n11. Agenda for training 11 Vaccine cold chain and storage Vaccination strategy Administration of vaccine, injection safety and waste disposal COVID-19 vaccine safety, warnings and contraindications Potential AEFI management and reporting Post vaccination counselling, evaluation and handling of emergencies\n\n12. Vaccine safety 12 Source: Vaccination Guide for Pakistan - Sinopharm Vaccine (Vero Cell) Safety in different age groups Safe and well tolerated from 18 years and above Most common AEFI Most common AEFI are pain at injection site and fever (mild/low grade) Vaccine immuno- genicity Tolerable and immunogenic in healthy people.\n\n13. Special Warnings 13 Source: Vaccination Guide for Pakistan - Sinopharm Vaccine (Vero Cell) 1. Intravascular (IV) injection is strictly prohibited 2. The patient should be under observation for at least 30 minutes after vaccination. 3. Health care workers who are under quarantine for recent exposure with COVID-19 case should not be allowed to vaccinate 4. Co-administration of Sinopharm vaccine with other vaccines should be avoided 5. Do not put the vaccine in contact with disinfectant or injection (when the protective cap is pulled off) 6. This vaccine should be used immediately after opening 7. Do not use the vaccine if foreign objects, unclear label, out of expiry and cracks in the syringe are seen\n\n14. Groups to which vaccine should not be administered 14 Source: Vaccination Guide for Pakistan - Sinopharm Vaccine (Vero Cell) Pregnant mother Lactating mother Children <18 years Patients who received SARS-CoV-2 monoclonal antibodies /convalescent plasma Immunodeficient Patients, individuals with anaphylaxis history Cancer patients, those who had organ transplant in past 1 year Individuals who are allergic to any component (active, excipients) of this vaccine Individuals who have received any vaccine in the past 14 days\n\n15. Agenda for training 15 Vaccine cold chain and storage Vaccination strategy Administration of vaccine, injection safety and waste disposal COVID-19 vaccine safety, warnings and contraindications Potential AEFI management and reporting Post vaccination counselling, evaluation and handling of emergencies\n\n16. Occurrence of adverse event following immunization (AEFI) 16 Note: No vaccine-related serious adverse reaction was observed Source: Vaccination Guide for Pakistan - Sinopharm Vaccine (Vero Cell) Very common • pain at the injection site Common • transient fever, • fatigue, • headache, • diarrhoea, • redness, • swelling, • itching, • hardening at the injection site Uncommon • skin rash at the injection site, • nausea and vomiting, • itching at the non-injection site, • muscle pain, • arthralgia, • drowsiness, • dizziness, etc. If there are any adverse events not mentioned here, please inform your physician in time.\n\n17. Adverse event following immunization (AEFI) reporting 17 Source: Vaccination Guide for Pakistan - Sinopharm Vaccine (Vero Cell) National Immunization Management System (NIMS) has a section to indicate any AEFI immediately After vaccine administration a feedback SMS after 48-72 hours will be auto-generated through NIMS, citizen can reply to register for any adverse event. • First SMS will be fired to ask whether the citizen has any adverse event or not (response will be either Yes or No) • If Yes; a second SMS will contain possible side effect with an IVR Code. Citizens can register for the adverse event through an IVR selection • The citizen can also report any untoward effect through the web-portal of NIMS or by calling to 1166 helpline. • The callers and doctors in the helpline have been trained to deal such emergency\n\n18. Role of AEFI focal persons in hospitals with Adult Vaccination Counters (AVCs) 18 Source: Vaccination Guide for Pakistan - Sinopharm Vaccine (Vero Cell) AEFI focal person should be notified in AVCs for emergency management of AEFI cases Requirements for the AEFI focal person: 1. A senior physician should be appointed as the AEFI focal person 2. The AEFI focal person must be oriented on AEFI management, include the following: • Serious AEFIs • Immunization errors • Clusters of AEFI (≥2 same AEFIs related in time, place & vaccine) • Concern of parents/caregivers and community regarding any minor or major AEFIs 3. Contact details of every AEFI focal person must be available with every Adult Vaccination Team (AVT)\n\n19. Management of AEFI in hospitals with AVCs 19 Source: Vaccination Guide for Pakistan - Sinopharm Vaccine (Vero Cell) 1. Early detection 2. Reporting 3. Clinical management (if required) 4. Reassurance of the target population • AEFI focal persons/doctors should be oriented on AEFI management • Each and every serious AEFI case should be thoroughly investigated following the national AEFI guidelines • Each and every AEFI to be reported in the AEFI reporting form and AEFI case investigation form by the AEFI focal person • Any serious AEFI must be immediately notified to the Provincial AEFI focal person • Death related to vaccination should be reported immediately • Data needs to be entered in the EPI- MIS for further investigation by the National AEFI review committee • The AVC must be prepared and well- equipped to manage any emergency case:  a qualified medical doctor  adequate stock of life saving medical supplies (with readable date of expiry)  functional oxygen cylinder • Ambulance arrangements must be in place and contact no. of the ambulance driver must be posted in the health facility and shared with the AEFI focal persons and team • Avoid possible rumours and misinformation • Only the designated AEFI focal person or a designated spokesperson should respond to the media and address rumours through social media • Crisis communication /risk communication strategy developed by Federal EPI must be adapted by DoH/ Provincial EPI prior to vaccine administration • Post-vaccination counselling is essential to provide accurate information\n\n20. Agenda for training 20 Vaccine cold chain and storage Vaccination strategy Administration of vaccine, injection safety and waste disposal COVID-19 vaccine safety, warnings and contraindications Potential AEFI management and reporting Post vaccination counselling, evaluation and handling of emergencies\n\n21. Post-vaccination counselling 21 Source: Vaccination Guide for Pakistan - Sinopharm Vaccine (Vero Cell) 1 HCWs should encourage the target population to complete 2-doses for maximum vaccine efficacy and benefit 2 Vaccinated individuals should be encouraged to report any adverse events following immunization 3 After vaccination, individuals should be advised to remain in waiting area of adult vaccination counter for at least 30 min to avoid any AEFI 4 Antipyretic or analgesic medication may be taken in case of fever/pain after vaccination\n\n22. Handling of post-vaccination emergencies (anaphylaxis) 22 Source: Vaccination Guide for Pakistan - Sinopharm Vaccine (Vero Cell) Patients should be managed as soon as possible and in an intensive care setting 1. Assess adequacy of ventilation and provide the patient with sufficient oxygen to maintain adequate oxygen saturation of at least 92% (pulse oximetry) 2. Equipment for endo-tracheal intubation should be available for immediate use in event of respiratory failure and is indicated for poor mentation, respiratory failure, or stridor not responding immediately to supplemental oxygen and epinephrine 3. Administer an isotonic solution such as normal saline 4. Patient should be kept under close observation for at least 6-8 hours after initial reaction"
    }
}